Effects of CYP2C9 and MDR1 polymorphism on the pharmacokinetics of losartan

被引：0
|
作者：
Bae, Jung-Woo
Han, Ho-Kyun
Lee, Hwan-Joo
Jung, Dong -Won
Kim, Nam-Tae
Lee, Jin-Hee
Jang, Choon-Gon
Choi, Sun-Ok
Kim, Ok-Hee
Lee, Seok-Yong
机构：
[1] Sungkyunkwan Univ, Coll Pharm, Seoul, South Korea
[2] Natl Inst Toxicol Res, Seoul, South Korea
来源：
ACTA PHARMACOLOGICA SINICA | 2006年 / 27卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
引用
收藏
页码：230 / 231
页数：2
相关论文
共 50 条
  • [31] The propagation of genetic polymorphism in CYP2C9 into warfarin pharmacokinetics: An integrated model
    Dickinson, GL
    Lennard, MS
    Tucker, GT
    Rostami-Hodjegan, A
    DRUG METABOLISM REVIEWS, 2005, 37 : 35 - 35
  • [32] Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2:: no relationship to the CYP2C9 genetic polymorphism in humans
    Kirchheiner, J
    Meineke, I
    Steinbach, N
    Meisel, C
    Roots, I
    Brockmöller, J
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 55 (01) : 51 - 61
  • [33] Disposition of a CYP2C9 phenotyping agent, losartan, is not influenced by the common 3435C > T variation of the drug transporter gene ABCB1 (MDR1)
    Yasar, Umit
    Babaoglu, Melih O.
    Bozkurt, Atila
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2008, 103 (02) : 176 - 179
  • [34] CYP2C9 polymorphism modifies blood pressure lowering response to losartan in type 1 diabetic nephropathy
    Lajer, M.
    Tarnow, L.
    Andersen, S.
    Parving, H. -H.
    DIABETOLOGIA, 2006, 49 : 137 - 138
  • [35] Effects of CYP2C9*3 and CYP2C9*13 alleles on the pharmacokinetics of celecoxib and its carboxylic metabolite.
    Park, So-Young
    Lee, Hye-In
    Choi, Chang-Ik
    PHARMACOTHERAPY, 2012, 32 (10): : E235 - E235
  • [36] THE INFLUENCE OF FLUCONAZOLE AND CYP2C9*3 ON CYP2C9 ACTIVITY, ASSESSED VIA LOSARTAN URINARY RATIO
    Anikin, G. S.
    Sychev, D. A.
    Ramenskaya, G., V
    Savchenko, A. Y.
    Ignatiev, I., V
    Dmitriev, V. A.
    Kukes, V. G.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2011, 109 : 153 - 153
  • [37] Effects of combined CYP2C9 and 2C19 polymorphism on the pharmacokinetics of glibenclamide in Chinese subjects.
    Yin, OQ
    Tomlinson, B
    Chow, MS
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P23 - P23
  • [38] Effects of CYP2C9*1/*3 genotype on the pharmacokinetics of flurbiprofen in Korean subjects
    Lee, Yun-Jeong
    Byeon, Ji-Yeong
    Kim, Young-Hoon
    Kim, Se-Hyung
    Choi, Chang-Ik
    Bae, Jung-Woo
    Sohn, Uy-Dong
    Jang, Choon-Gon
    Lee, Jeongmi
    Lee, Seok-Yong
    ARCHIVES OF PHARMACAL RESEARCH, 2015, 38 (06) : 1232 - 1237
  • [39] Effects of CYP2C9*1/*3 genotype on the pharmacokinetics of flurbiprofen in Korean subjects
    Yun-Jeong Lee
    Ji-Yeong Byeon
    Young-Hoon Kim
    Se-Hyung Kim
    Chang-Ik Choi
    Jung-Woo Bae
    Uy-Dong Sohn
    Choon-Gon Jang
    Jeongmi Lee
    Seok-Yong Lee
    Archives of Pharmacal Research, 2015, 38 : 1232 - 1237
  • [40] Effect of CYP2C9 genotype on losartan disposition.
    Pieper, JA
    Lee, CR
    Hinderliter, AL
    Clarke, MJ
    Blaisdell, JA
    Goldstein, JA
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (02) : P68 - P68
12345